Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

401. Risk of Post-COVID Conditions Correlates with IL-6 Plasma Levels and Is Reduced by Early Antibody Therapy
Fukuta, Yuriko , Heath, Sonya L. , Baksh, Sheriza , Habtehyimer, Feben , Shade, David , Ruff, Jessica E. , Ram, Malathi , Fernández, Reinaldo E. , Baker, Owen R. , Cachay, Edward R. , Gerber, Jonathan M. , Hammitt, Laura L. , Forthal, Donald N. , Patel, Bela, Gniadek, Thomas J. , Blair, Janis E. , Lane, Karen , McBee, Nichol , Gawad, Amy L., Das, Piyali, Bloch, Evan M. , Gebo, Kelly A , Zhu, Xianming , Abraham, Alison G. , Laeyendecker, Oliver , Patel, Eshan U. , Shoham, Shmuel , Currier, Judith S. , Meisenberg, Barry R. , Huamán, Moisés A. , Levine, Adam C , Mosnaim, Giselle S , Paxton, James H , Raval, Jay S. , Sutcliffe, Catherine G , Anjan, Shweta , Kassaye, Seble , Klein, Sabra L , Pekosz, Andrew , Hanley, Daniel F. , Casadevall, Arturo , Tobian, Aaron A.R. , Sullivan, David

Mayo Clinic

Open Forum Infectious Diseases | November 27, 2023 | Volume: 10 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofad500.471 Get It

Abstract Background Post-COVID conditions (PCC) are common, and risk factors include older age and female sex. While high interleukin (IL)-6 and C-reactive protein are associated with more severe disease, it is unclear whether other cytokines are associated with PCC. This study was performed to identify factors associated with PCC development. Methods The Convalescent Plasma to Limit SARS-CoV-2 Associated Complications (CSSC-004) trial was a double-blind, multi-center, randomized, controlled trial comparing the use of COVID-19 convalescent plasma (CCP) to control plasma for the prevention of hospitalization among COVID-19 outpatients. Among 882 individuals participating in the trial with available biospecimens and symptom data, the association between early COVID-19 treatment, cytokine levels and PCC was evaluated. Cytokine and chemokine levels were assessed at baseline, day 14 and day 90 using a multiplexed sandwich immuosassay. Presence of any PCC symptom was assessed at day 90. Associations between COVID-19 treatment, cytokine levels and PCC were examined using multivariate logistic regression models. Results Baseline characteristics were similar by trial treatment group (Figure 1). At day 90, 292 (33.1%) participants had PCC. The most common symptoms were fatigue (14.5%), anosmia (14.5%), and ageusia (10.0%). Levels of most cytokines decreased over time (Figure 2). Six pro-inflammatory cytokines especially IL-6 were elevated at baseline among those with PCC (Figure 3). In multivariable analysis, female sex (adjusted odds ratio [AOR]=2.70[1.93-3.81]), age 50 or greater (AOR=1.32[1.17-1.50]), and elevated baseline IL-6 (AOR=1.59[1.02-2.47]) were associated with development of PCC, whereas race, obesity, vaccine status and diabetes were not. Those who received early CCP treatment (<5 days after symptom onset) compared to late CCP treatment had statistically significant lower odds of PCC (AOR=0.60 [0.38-0.95]). Conclusion This study showed high prevalence of PCC symptoms at day 90, particularly among those with higher baseline levels of IL-6 or who did not receive early CCP treatment. The potential utility of IL-6 modulation as a therapeutic intervention among individuals as higher risk for PCC should be studied. Disclosures Kelly Gebo, MD, MPH, Pfizer: Advisor/Consultant|Spark HealthCare: Advisor/Consultant Sonya L. Heath, MD, Pfizer: Data Monitoring Committee/DSMB Shmuel Shoham, MD, adagio: Advisor/Consultant|Adamis: Advisor/Consultant|ansun: Grant/Research Support|Avir Pharma: Honoraria|cidara: Grant/Research Support|F2G: Grant/Research Support|Immunome: Advisor/Consultant|Karius: Honoraria|Scynexis: Advisor/Consultant|zeteo: Grant/Research Support Judith S. Currier, M.D., MSc, Merck and Company: Advisor/Consultant|Merck and Company: Honoraria Moises A. Huaman, MD, MSc, AN2 Therapeutics Inc: Grant/Research Support|Gilead Sciences Inc: Grant/Research Support|Insmed Inc: Grant/Research Support Jay S. Raval, MD, Sanofi Genzyme: Advisor/Consultant Arturo Casadevall, MD, PhD, Ortho Diagnostics: Speakers Bureau|Sabtherapeutics: Advisor/Consultant
1349. Unveiling the Link between COVID-19 and the Gut Microbiome in an Outpatient Cohort with Mild to Moderate Illness
Gorp, Trena Van, Harrington, Jonathan J. , Kashyap, Purna , Comba, Işın Y. , Mars, Ruben A. , Dumais, Mitchell , Gorp, Trena M. Van, O’Horo, John C.

Mayo Clinic

Open Forum Infectious Diseases | November 27, 2023 | Volume: 10 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofad500.1186 Get It

Abstract Background As the acute phase of the COVID-19 pandemic subsides, an increasing number of individuals are recognized as having long COVID, affecting over 65 million people worldwide. Recent studies have suggested a potential link between long COVID and alterations in the gut microbiome. In this study, we examined the gut microbiome of a large outpatient cohort during acute phase of infection, with the ultimate goal of determining predictors of long-term COVID-19 health outcomes. Methods We conducted a study of 394 COVID-19 patients with positive SARS-CoV-2 testing from November 2020 to September 2021 at a multi-site healthcare system. Long COVID was defined as the persistence of symptoms for four weeks or more after illness onset. DNA extraction was performed using the MoBio PowerSoil Pro DNA isolation kit. Samples were sequenced using shotgun metagenomics. Stool SARS-CoV-2 RNA was tested using qRT-PCR of the E gene, and stool ELISA was performed for calprotectin levels. Standard biostatistical tools in R (v 4.2.3) were used for statistical analysis. Results Of the 394 COVID-19 patients, 84 (21%) had long COVID, with fatigue being the most common persistent symptom (Table 1). No significant differences were seen in age, BMI, and antibiotic use. Those with long COVID were more likely to be female, had higher Charlson's comorbidity scores, more severe index illnesses. However, the two groups had no difference in SARS-CoV-2 stool PCR positivity or stool calprotectin levels (Table 2). Principal coordinate analysis of Bray Curtis dissimilarities revealed that patients with long COVID had a distinct microbial composition compared with those without long COVID during the acute phase of infection (ANOSIM R2= 0.005, P= 0.01). Categorizing patients by number of long COVID symptoms showed significant differences among groups (ANOSIM R2=0.1, P=0.007), mainly between patients with >3 symptoms and those with 0-1 symptoms (Bonferroni, P= 0.018). Alpha diversity was lower in patients with > 3 symptoms, although this was not statistically significant (Shannon diversity, two-way-ANOVA, P=0.051). Figure 1 Conclusion Long COVID patients show distinct gut microbial composition during the acute phase of infection, suggesting a potential role in predicting long-term COVID health outcomes. Disclosures John C. O'Horo, Sr., MD, MPH, Janssen Pharmaceuticals.: Grant/Research Support|nference: Grant/Research Support Purna C. Kashyap, MD, Intrinsic Medicine: Advisor/Consultant|Novome Biotechnologies: Advisor/Consultant|Pendulum Therapeutics: Advisor/Consultant
1779. Trends in Anaplasmosis Over the Past Decade: A Review of Clinical Features, Laboratory Data and Outcomes
Chesdachai, Supavit , Wilcock, Jonathan , Saleh, Omar Abu , Chesdachai, Supavit , Katragadda, Silpita , Yetmar, Zachary A. , Ranganath, Nischal , Challener, Douglas W.

Mayo Clinic

Open Forum Infectious Diseases | November 27, 2023 | Volume: 10 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofad500.1608 Get It

Abstract Background Human granulocytic anaplasmosis (HGA) is an emerging tick-borne illness endemic to the northeastern and midwestern United States. Risk factors for the severity of infection, predictors for hospitalization, temporal trends, co-infections, and outcomes are poorly studied. Methods We conducted a retrospective review of HGA at Mayo Clinic, Rochester, between 2011-2021. Cases were identified by positive Anaplasma PCR at our reference laboratory. Variables included patients’ characteristics, symptoms, risk factors for tick-borne illness, laboratory parameters, co-infections, treatment, and clinical outcomes. Results We identified 471 cases with a positive Anaplasma PCR, and 146 cases were included in this interim analysis. Table 1 shows a summary of the baseline characteristics. An increasing annual trend in diagnosis of HGA was noted from 2014 to 2016 with lower rates observed during COVID-19 pandemic (2020 to 2022) (Figure 1). Of the 146 patients, 19 (13%) were immunocompromised secondary to hematologic malignancies, solid organ malignancies, and pharmacological immunosuppression. Frequently reported symptoms included fever (79.5%), malaise (68.5%), chills (51.4%), and myalgia (50%). Tick exposure was documented in 79.2 % of cases. Forty-seven (33%) patients were hospitalized; older patients were more likely to be hospitalized (Table 2). The most common complications among the hospitalized patients included respiratory failure (50%), encephalopathy (44.4%) and renal failure (37.5%). One patient required ICU admission. Twenty-five patients (17.5%) and one patient (0.7%) were co-infected with Lyme and Ehrlichiosis, respectively. Higher rates of leukopenia and thrombocytopenia were associated with mono-infection with Anaplasma (p < 0.001). Follow up data was available for 136 patients; all of them had favorable response to doxycycline.Table 1:Summary of baseline characteristics, labs and treatment.Table 2:Predictors of HospitalizationFigure 1:Annual Trends in Anaplasmosis from 2011-2021. Conclusion Our study demonstrated comprehensive clinical characteristics of patients with HGA. Interestingly, tick exposure history was common, yet most patients did not have other tick-borne co-infections. Furthermore, only a minority of patients developed severe diseases and required hospitalization. The recent decline in cases during the early part of the COVID-19 pandemic is worth further investigation. Disclosures All Authors: No reported disclosures
Lung Mechanics and Structure in Aged C57BL/6x129 Mice
Omar, Tanya S., Elliott, Jonathan E. , Mantilla, Carlos B. , Sieck, Gary C.

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 30 | Issue: S1 | Pages: No page available

10.1096/fasebj.30.1_supplement.1297.3 Get It

Aging‐related changes in lung mechanics of human subjects are characterized by a decrease in resistance and an increase in static compliance (decrease in elastic recoil). Together, these changes result in an increase in residual volume in the absence of an increase in total lung capacity. In C57BL/6x129 mice, it was reported that lung compliance increases with aging while elastic recoil pressure does not change. However, in these studies, “old” mice at 24 months of age were compared to “young” mice at 2 months of age, but at this younger age, alveologenesis is incomplete (completion does not occur until ~6 months of age). Accordingly, it remains to be established if the same aging‐related changes in lung mechanics are observed using fully developed adult C57BL/6x129 mice for comparison. To this end, we compared lung mechanics in C57BL/6x129 mice at 6 months (100% survival, n = 6), 18 months (90% survival, n = 6), and 24 months (75% survival, n = 6) of age. Respiratory system static mechanics (Resistance, R rs ; Compliance, C rs ; Elastance, E rs ) were assessed following tracheal intubation using the FlexiVent. There was a progressive aging‐related decrease in R rs (6 month, 0.47 ± 0.02; 18 month, 0.41 ± 0.02; 24 month, 0.35 ± 0.02 cmH 2 O.s/ml), an increase in C rs (6 month, 0.046 ± 0.002; 18 month, 0.052 ± 0.002; 24 month, 0.062 ± 0.002 ml/cmH 2 O), and a decrease in E rs (6 month, 21.73 ± 1.19; 18 month, 19.30 ± 0.87; 24 month, 16.62 ± 1.25 cmH 2 O/ml). Additionally, lungs were fixed following tracheal instillation of 4% paraformaldehyde at 25 cmH 2 O. Thereafter, lungs were dehydrated, paraffin embedded, sectioned (6 μm thick), and stained (hematoxylin and eosin). Using standard stereological approaches, lung sections were analyzed in a uniform systematic but random fashion to assess alveolar morphology (measurement of average distance between alveolar walls based on mean linear intercept, L m ). There was a progressive aging‐related increase in L m (6 month, 34 ± 2; 18 month, 40 ± 2; 24 month, 45 ± 2 μm) consistent with an aging‐related emphysematous‐like change in lung morphometry. Taken together, these results in appropriately aged C57BL/6x129 mice demonstrate an aging‐related change in lung mechanics and morphometry consistent with what is observed in aging humans. Therefore, the results of the present study confirm the use of rodent models for studying aging‐related changes in lung mechanics and morphometry. Support or Funding Information National Institute of Health grants R01‐AG044615 (CBM & GCS) and T32‐HL105355 (JEE).
Diaphragm Muscle Sarcopenia in Fischer 344 and Brown Norway Rats
Omar, Tanya S., Elliott, Jonathan E. , Mantilla, Carlos B. , Sieck, Gary C.

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 30 | Issue: S1 | Pages: No page available

10.1096/fasebj.30.1_supplement.1295.1 Get It

The risk for respiratory diseases is significantly increased in the elderly population (>65 years of age), which may be partially due to an inability to adequately clear the airways resulting from a progressive aging‐related atrophy and weakening (i.e., sarcopenia) of the diaphragm muscle (DIAm). In humans, reduced maximum inspiratory and transdiaphragmatic pressures suggest DIAm weakening, but muscle fiber atrophy has not been examined. In a National Institute on Aging (NIA) supported mouse model of aging (C57BL/6J strain), we recently showed that DIAm sarcopenia exists and affects non‐ventilatory functions (Greising et al., Exp Gerontol 48:881–887, 2013; Greising et al., Am J Physiol Lung Cell Mol Physiol 309:46–52, 2015). Importantly, rodent models such as this provide a valuable tool to explore the mechanisms underlying DIAm sarcopenia. Currently, the NIA also provides two inbred rat models for aging‐related research: the Fischer 344 (F344) and Brown Norway (BN) rat strains. The purpose of this study was to comprehensively examine whether sarcopenia also exists in the DIAm of F344 and BN rat strains provided by the NIA. Young (6 month, 100% survival) and old (24 month, 50% survival) F344 and young (6 month, 100% survival) and old (32 month, 50% survival) BN male, pathogen free, rats were obtained from the NIA rodent colony. In DIAm strips from the right midcostal region, measurements of contractility, contractile protein concentration, relative myosin heavy chain (MyHC) isoform expression, fiber type distribution and fiber cross‐sectional area (CSA) were obtained. Peak twitch specific force (P t ) was reduced by ~17% and ~14% in the aged F344 and BN rats, respectively. Additionally, maximal specific force (P o ) was reduced by ~24% and ~12% in the aged F344 and BN rats, respectively. Thus, although there was significant aging‐related DIAm weakness in both rat strains, reductions in both P t and P o were more pronounced in old F344 compared to BN rats. In F344 rats, aging also affected DIAm fiber type proportions with a significant increase in the proportion of type I fibers in old (45 ± 3%), compared to young (35 ± 3%) rats, with a concomitant decrease in the relative proportions of both type IIa fibres and type IIx and/or IIb fibers. In BN rats, DIAm fiber type proportions were not affected by aging. In both F344 and BN rats, the CSA of type I and IIa fibers were unchanged, whereas the CSA of type IIx and/or IIb DIAm fibers were reduced by ~20% in F344 rats and by ~15% is BN rats. Similar to DIAm weakness, the selective aging‐related atrophy of type IIx and/or IIb DIAm fibers was more pronounced in F344 rats. In conclusion, DIAm sarcopenia is clearly present in both F344 and BN rat strains, but more pronounced in the F344 strain. These results indicate that in addition to the C57BL/6J mouse model, the F344 rat strain is an appropriate model for research pertaining to DIAm sarcopenia. Support or Funding Information Support: National Institute of Health grants R01‐AG044615 (CBM & GCS) and T32‐HL105355 (JEE).
An Analysis of Political Contributions from Otolaryngologists in the United States
Fish, Taylor R. , Lefkowitz, Jonathan , Galar, Federico , Markham, Dane J. , Imber, Paul, Denneny, James C. , Chen, Philip G , Chen, Philip G.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | November 24, 2023 | Volume: 170 | Issue: 3 | Pages: 804-811

10.1002/ohn.585 | PMID 37997397 Get It

AbstractObjectiveDoctors can influence the development of sound healthcare policy through financial contributions to political campaigns and candidates. Our objective was to characterize the political contributions of otolaryngologists in the United States, both individually and through the ENT Political Action Committee (ENTPAC) between the years 2003 and 2020.Study DesignRetrospective observational study.SettingPublicly available information on the internet: fec.gov.MethodsThe Federal Election Commission's website, fec.gov, was used to identify the political contributions of individual otolaryngologists and the ENTPAC between 2003 and 2020. Each contribution is associated with a political group or candidate, designated as a Republican, Democratic, or Independent entity.ResultsA total of 1407 distinct political contributions were made by individuals identifying as otolaryngologists between 2003 and 2020, totaling $432,201. Overall, Republicans received more individual donations than Democrats (711 vs 540), while Democrats received more money ($231,139 vs $183,427). Donations peaked during election years, with the total amount overall increasing each election year ($9664 in 2004 vs $75,102 in 2020). The predominant political party receiving donations between 2003 and 2020 in each US state matched each state's predominant party of the governors and senators 48.6% of the time. The ENTPAC donated $3,027,383 between 2003 and 2020 to a variety of political candidates and entities.ConclusionOtolaryngologists are making increased political contributions over time and interest in political advocacy may be at an all‐time high. Increased time and attention should be devoted to educating otolaryngologists to best politically advocate for interests which are of the most importance to themselves and the profession.
Impact of Successful Recanalization and Clinical Outcomes of Patients With Acute Ischemic Stroke with 5 or More Thrombectomy Passes
Uchida, Kazutaka , Kasab, Sami Al , Maier, Ilko , Jabbour, Pascal , Kim, Joon‐Tae , Rai, Ansaar , Starke, Robert M. , Psychogios, Marios‐Nikos , Grossberg, Jonathan A , Tanweer, Omar , Polifka, Adam , Park, Min S. , Brinjikji, Waleed , Moss, Mark, Williamson, Richard , Navía, Pedro , Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Collaborators, for the Stroke Thrombectomy and Aneurysm Registry (STAR), Navia, Pedro , Sowlat, Mohammad‐Mahdi , Matsukawa, Hidetoshi , Elawady, Sameh Samir , Alawieh, Ali , Cunningham, Conor M. , Jabbour, Pascal , Wolfe, Stacey Q , Shaban, Amir , Arthur, Adam Stephen , Cuellar, Hugo , Romano, Daniele G., Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Crosa, Roberto , Matouk, Charles , Levitt, Michael R. , Leacy, Reade De , Yoshimura, Shinichi , Collaborators, for the Stroke Thrombectomy and Aneurysm Registry (STAR)

Mayo Clinic

Stroke: Vascular and Interventional Neurology | November 21, 2023 | Volume: 4 | Issue: 1 | Pages: No page available

10.1161/svin.123.001107 | PMID 41586058 Get It

Background As the number of thrombectomy passes increases during endovascular therapy (EVT) for acute stroke, neurointerventionalists must weigh the risks of potential complications against the risk of failing to recanalize the affected vessel. Thus, we investigated the effectiveness and safety of EVT for patients with acute stroke in which ≥5 EVT passes were performed. Methods This retrospective cohort study from January 2013 to December 2022 included 31 thrombectomy‐capable centers. Patients in whom ≥5 EVT passes were made were included in the analysis. The patients with successful recanalization defined as modified Thrombolysis in Cerebral Infarction ≥2b at 5, 6, 7, or more passes were compared with unsuccessful recanalization. We also compared procedure time, separated by 30 minutes. Primary outcome was a favorable 90‐day outcome (modified Rankin scale score of 0–2). Secondary outcomes were intracranial hemorrhage and death. Results A total of 407 patients met the inclusion criteria, of which 175 were women (43.1%); the mean age was 67.3 years. In 265 (65.1%) patients, successful recanalization was achieved: 134 patients with 5 passes, 67 patients with 6 passes, and 64 with ≥7 passes. Intravenous recombinant tissue plasminogen activator administration was more common in the unsuccessful recanalization group (successful recanalization with 5, 6, and ≥7 EVT passes and unsuccessful recanalization: 35.3%, 30.3%, 18.8%, and 45.4%, respectively). Successful recanalization with 5, 6, and ≥7 EVT passes was associated with favorable outcome compared with unsuccessful recanalization group (adjusted odds ratio successful recanalization with 5, 6, and ≥7 EVT passes to unsuccessful recanalization [95% CIs]: 8.29 [2.13–32.3]; 14.0 [3.27–60.3]; and 5.26 [1.12–24.8], respectively). However, symptomatic intracranial hemorrhage was not significantly different between the groups. Regarding procedure time, favorable outcome was not significantly different in each group, while symptomatic intracranial hemorrhage occurred more frequently in the 60 to 89 minutes group compared with the <30 minutes group (adjusted odds ratio, 60–89 minutes group to <30 minutes group [95% CI]: 5.86 [1.09–31.6]). Conclusion These findings suggest that a benefit in outcome persists for recanalization, without significant increase in complications. In addition, there was no significant difference in favorable outcomes among procedure time.
Is It Time to Reconsider the Concept of “Salvage Therapy” in Refractory Shock?*
Wieruszewski, Patrick M. , Sevransky, Jonathan, Roberts, Russel J. , Wieruszewski, Patrick M

Mayo Clinic

Critical Care Medicine | November 16, 2023 | Volume: 51 | Issue: 12 | Pages: 1821-1824

10.1097/ccm.0000000000006003 | PMID 37971337 Get It

Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1
Staniszewska, Anna D. , Pilger, Domenic , Gill, Sonja J. , Jamal, Kunzah , Bohin, Natacha , Guzzetti, Sofia , Gordon, Jacob , Hamm, Gregory , Mundin, Gill , Illuzzi, Giuditta , Rose, Jonathan , Hawthorne, Glen , González, Miguel A. Cortés , Halldin, Christer , Johnström, Peter , Schou, Magnus , Johannes, Jeffrey W. , Davies, B. R. , Cosulich, Sabina , O’Connor, Mark J. , Pike, Andy , McWilliams, Lisa , Maglennon, Gareth , Rose, Jonathan , Hawthorne, Glen , Cortes Gonzalez, Miguel , Halldin, Christer , Johnström, Peter , Schou, Magnus , Critchlow, Susan E , Fawell, Stephen , Johannes, Jeffrey W , Leo, Elisabetta , Davies, Barry R , Cosulich, Sabina , Sarkaria, Jann N , O'Connor, Mark J , Hamerlik, Petra , Sarkaria, Jann N. , Hamerlik, Petra

Mayo Clinic

Clinical Cancer Research | November 15, 2023 | Volume: 30 | Issue: 7 | Pages: 1338-1351

10.1158/1078-0432.ccr-23-2094 | PMID 37967136 Get It

Abstract Purpose: We evaluated the properties and activity of AZD9574, a blood–brain barrier (BBB) penetrant selective inhibitor of PARP1, and assessed its efficacy and safety alone and in combination with temozolomide (TMZ) in preclinical models. Experimental Design: AZD9574 was interrogated in vitro for selectivity, PARylation inhibition, PARP-DNA trapping, the ability to cross the BBB, and the potential to inhibit cancer cell proliferation. In vivo efficacy was determined using subcutaneous as well as intracranial mouse xenograft models. Mouse, rat, and monkey were used to assess AZD9574 BBB penetration and rat models were used to evaluate potential hematotoxicity for AZD9574 monotherapy and the TMZ combination. Results: AZD9574 demonstrated PARP1-selectivity in fluorescence anisotropy, PARylation, and PARP-DNA trapping assays and in vivo experiments demonstrated BBB penetration. AZD9574 showed potent single agent efficacy in preclinical models with homologous recombination repair deficiency in vitro and in vivo. In an O6-methylguanine-DNA methyltransferase (MGMT)–methylated orthotopic glioma model, AZD9574 in combination with TMZ was superior in extending the survival of tumor-bearing mice compared with TMZ alone. Conclusions: The combination of three key features—PARP1 selectivity, PARP1 trapping profile, and high central nervous system penetration in a single molecule—supports the development of AZD9574 as the best-in-class PARP inhibitor for the treatment of primary and secondary brain tumors. As documented by in vitro and in vivo studies, AZD9574 shows robust anticancer efficacy as a single agent as well as in combination with TMZ. AZD9574 is currently in a phase I trial (NCT05417594). See related commentary by Lynce and Lin, p. 1217
Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET
Therneau, Terry M. , Wiste, Heather J. , Graff‐Radford, Jonathan , Lowe, Val J. , Gunter, Jeffrey L. , Vemuri, Prashanthi , Petersen, Ronald C. , Jack, Clifford R. , Lundt, Emily S. , Jack, Clifford R , Vemuri, Prashanthi , Cogswell, Petrice M. , Algeciras‐Schimnich, Alicia , Mielke, Michelle M. , Schwarz, Christopher G. , Senjem, Matthew L. , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | November 14, 2023 | Volume: 20 | Issue: 2 | Pages: 1225-1238

10.1002/alz.13539 | PMID 37963289 Get It

Abstract INTRODUCTION The timing of plasma biomarker changes is not well understood. The goal of this study was to evaluate the temporal co‐evolution of plasma and positron emission tomography (PET) Alzheimer's disease (AD) biomarkers. METHODS We included 1408 Mayo Clinic Study of Aging and Alzheimer's Disease Research Center participants. An accelerated failure time (AFT) model was fit with amyloid beta (Aβ) PET, tau PET, plasma p‐tau217, p‐tau181, and glial fibrillary acidic protein (GFAP) as endpoints. RESULTS Individual timing of plasma p‐tau progression was strongly associated with Aβ PET and GFAP progression. In the population, GFAP became abnormal first, then Aβ PET, plasma p‐tau, and tau PET temporal meta‐regions of interest when applying cut points based on young, cognitively unimpaired participants. DISCUSSION Plasma p‐tau is a stronger indicator of a temporally linked response to elevated brain Aβ than of tau pathology. While Aβ deposition and a rise in GFAP are upstream events associated with tau phosphorylation, the temporal link between p‐tau and Aβ PET was the strongest. Highlights Plasma p‐tau progression was more strongly associated with Aβ than tau PET. Progression on plasma p‐tau was associated with Aβ PET and GFAP progression. P‐tau181 and p‐tau217 become abnormal after Aβ PET and before tau PET. GFAP became abnormal first, before plasma p‐tau and Aβ PET.